Cargando…
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
An orphan medicinal product, eculizumab is approved in Japan and globally for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab therapy can cause late complement pathway deficiencies that predispose patients to meningococcal infections. Although meningoc...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990028/ https://www.ncbi.nlm.nih.gov/pubmed/24716834 http://dx.doi.org/10.1186/1750-1172-9-48 |